[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603935":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":52,"collaborators":20,"id":54,"slug":20,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HRS-7172 Group","EXPERIMENTAL","Oral HRS-7172.",[13],"Drug: HRS-7172 Tablets",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","HRS-7172 Tablets","HRS-7172 tablets.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Rongfu Mao","CONTACT","+86-021-61053363","rongfu.mao@hengrui.com",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},"Jizhao Li","jizhao.li.jl565@hengrui.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Fudan University Affiliated Cancer Hospital","RECRUITING","Shanghai","Shanghai Municipality","200032","China","CN",{"type":40,"coordinates":41},"Point",[42,43],121.45806,31.22222,{"lat":43,"lon":42},[46,50],{"name":47,"role":24,"phone":48,"phoneExt":20,"email":49},"Xianjun Yu","+86-021-64175590","yuxianjun@fudanpci.org",{"name":47,"role":51,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100603935",false,"NCT07142980","A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","A Phase I Study of HRS-7172 Evaluating Safety, Tolerability and Pharmacokinetics in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","Inclusion Criteria:\n\n1. Have fully understood this study and are willing to sign the ICF, with good compliance and cooperation in follow-up;\n2. Aged between 18-75 years old;\n3. ECOG performance status (PS) score of 0 or 1;\n4. Life expectancy \\> 3 months;\n5. At least one measurable lesion per RECIST v1.1;\n6. Adequate organ function.\n\nExclusion Criteria:\n\n1. Toxicity from prior anti-tumor treatment has not recovered to Grade ≤ 1 or a level specified in the inclusion\u002Fexclusion criteria;\n2. Presence of central nervous system (CNS) metastases;\n3. Participants with gastrointestinal diseases that affect drug administration\u002Fabsorption;\n4. Participants who have undergone major surgery other than diagnosis or biopsy within 28 days before the first dose, or are expected to undergo major surgery during the study period;\n5. Presence of serious pulmonary diseases;\n6. Active tuberculosis or a history of active tuberculosis infection within 48 weeks prior to screening, regardless of whether they have been treated;\n7. Active or persistent gastrointestinal bleeding within 6 months prior to screening;\n8. History of allogeneic bone marrow or solid organ transplantation;\n9. History of deep vein thrombosis or pulmonary embolism within 6 months prior to screening;\n10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring clinical intervention;\n11. Positive human immunodeficiency virus (HIV) (HIV1\u002F2 antibodies), active chronic hepatitis B, or active hepatitis C (positive HCV antibody and positive HCV RNA);\n12. Known history of hypersensitivity to any component of the drug product to be used in the study.","ALL","18 Years","75 Years",{"count":64,"type":65},120,"ESTIMATED","INTERVENTIONAL",[68],"PHASE1","This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.",[71],"Advanced Solid Tumors Harboring RAS Mutations or Amplifications","2025-11-13",{"date":74,"type":75},"2025-11-17","ACTUAL",{"date":77,"type":75},"2025-09-12",{"date":79,"type":65},"2028-12",{"name":5,"class":6},1]